Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.

Dhillon S.

Drugs. 2013 Sep;73(13):1451-62. doi: 10.1007/s40265-013-0098-z. Review.

PMID:
23881669
2.

Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).

Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASIS-HF Investigators..

J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93. doi: 10.1016/j.jacc.2013.04.086. Epub 2013 Jun 27.

3.

Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.

Girerd N, Collier T, Pocock S, Krum H, McMurray JJ, Swedberg K, Van Veldhuisen DJ, Vincent J, Pitt B, Zannad F.

Eur Heart J. 2015 Sep 7;36(34):2310-7. doi: 10.1093/eurheartj/ehv273. Epub 2015 Jun 20.

PMID:
26093641
4.

Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.

Krum H, Shi H, Pitt B, McMurray J, Swedberg K, van Veldhuisen DJ, Vincent J, Pocock S, Zannad F; EMPHASIS-HF Study Group..

Circ Heart Fail. 2013 Jul;6(4):711-8. doi: 10.1161/CIRCHEARTFAILURE.112.000173. Epub 2013 Apr 26.

5.

Eplerenone in chronic heart failure with depressed systolic function.

Volterrani M, Iellamo F.

Int J Cardiol. 2015 Dec 1;200:12-4. doi: 10.1016/j.ijcard.2015.05.126. Epub 2015 May 21. Review.

PMID:
26044084
6.

Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).

Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B.

Eur J Heart Fail. 2010 Jun;12(6):617-22. doi: 10.1093/eurjhf/hfq049. Epub 2010 Apr 13.

7.

Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.

Barnes BJ, Howard PA.

Ann Pharmacother. 2005 Jan;39(1):68-76. Epub 2004 Dec 8. Review. Erratum in: Ann Pharmacother. 2005 May;39(5):978.

PMID:
15590870
8.
9.

The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.

Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B.

Eur Heart J. 2013 Sep;34(36):2823-9. doi: 10.1093/eurheartj/eht247. Epub 2013 Jul 17.

PMID:
23864130
10.

Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.

Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC.

J Card Fail. 2012 Apr;18(4):265-81. doi: 10.1016/j.cardfail.2012.02.005.

PMID:
22464767
11.

Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study.

Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B; EMPHASIS-HF Study Investigators..

J Am Coll Cardiol. 2012 May 1;59(18):1598-603. doi: 10.1016/j.jacc.2011.11.063.

12.

Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations.

Rogers JK, McMurray JJ, Pocock SJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B.

Circulation. 2012 Nov 6;126(19):2317-23. doi: 10.1161/CIRCULATIONAHA.112.110536. Epub 2012 Oct 5.

13.

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.

Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJ; Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Study..

Heart. 2014 Nov;100(21):1681-7. doi: 10.1136/heartjnl-2014-305673. Epub 2014 Jul 3.

14.
15.

Eplerenone in patients with systolic heart failure and mild symptoms.

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group..

N Engl J Med. 2011 Jan 6;364(1):11-21. doi: 10.1056/NEJMoa1009492. Epub 2010 Nov 14.

16.

Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF.

Jacob MS, Tang WH.

Curr Heart Fail Rep. 2011 Mar;8(1):7-13. doi: 10.1007/s11897-010-0046-0.

PMID:
21207206
17.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators..

N Engl J Med. 2003 Apr 3;348(14):1309-21. Epub 2003 Mar 31. Erratum in: N Engl J Med. 2003 May 29;348(22):2271.

18.

Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).

Capuano A, Scavone C, Vitale C, Sportiello L, Rossi F, Rosano GM, Coats AJ.

Int J Cardiol. 2015 Dec 1;200:15-9. doi: 10.1016/j.ijcard.2015.07.038. Review.

PMID:
26404747
19.

The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.

Davis KL, Nappi JM.

Clin Ther. 2003 Nov;25(11):2647-68. Review.

PMID:
14693297
20.

Integrating traditional and emerging treatment options in heart failure.

Nolan PE Jr.

Am J Health Syst Pharm. 2004 May 1;61 Suppl 2:S14-22. Review.

PMID:
15160834

Supplemental Content

Support Center